 |
|
 |
AIDS & HIV |
|
|
HIV - Novel Nnrtis Address Crucial Unmet Need
Pipeline Insight
Publication Date December 2007
Publisher Datamonitor
Product Type Report
Pages 184
ISBN Number not applicable
Product Code DAT1145
|
|
|
Summary
Introduction
Treatment of HIV has come a long way since the discovery of the virus. Although no real cure has been found yet, the last few decades have seen the introduction of many classes of drugs that suppress the replication of the virus. As therapeutics have improved dramatically in terms of efficacy, safety and convenience, the bar for new drugs has been raised considerably.
Scope
- In-depth analysis of Phase II and III clinical development compounds and comprehensive overview of Phase I drugs
- Overview of the key companies involved in the HIV pipeline
- The epidemiology dynamics of HIV in the six major markets are discussed along with unmet needs that have evolved from the prolonged use of HAART
- Sales forecasts over the next 10 years for the each of the late-stage drugs
Highlights
Class drug resistance represents a major problem for the NNRTIs. The two late stage compounds, developed by Tibotec/J&J, address this issue. etravirine is the more advanced of the two, but rilpivirine convenient dosing schedule makes it the commercially more promising candidate.
New NRTIs in development have not generated much excitement in the HIV community since most of these compounds, including Avexa's apricitabine, Achillion's elvucitabine and Pharmasset's Racivir. have only made slow progress over the last few years.
Historically, emerging drug resistance may have signaled overall treatment failure and hastened the onset of AIDS. While newer classes of drugs will enable patients with complex drug resistance to continue with successful antiretroviral therapy, exactly how they will be incorporated into traditional HAART regimens remains unclear at this stage.
Reasons to Purchase
- Understand the constantly evolving market dynamics of antiretroviral drugs
- Understand the changing unmet needs of patients and the extent to which pipeline drugs are addressing these issues
- Evaluate the forecast of key pipeline antiretroviral drugs to 2016, taking into account key launch dates, adressing of unmet needs and other factors
|
Content
- Introduction
- Treatment Of Hiv Has Come A Long Way Since The Discovery Of The Virus. Although No Real Cure Has Been Found Yet, The Last Few Decades Have Seen The Introduction Of Many Classes Of Drugs That Suppress The Replication Of The Virus. As Therapeutics Have Improved Dramatically In Terms Of Efficacy, Safety And Convenience, The Bar For New Drugs Has Been Raised Considerably.
- Scope
- In-Depth Analysis Of Phase Ii And Iii Clinical Development Compounds And Comprehensive Overview Of Phase I Drugs Overview Of The Key Companies Involved In The Hiv Pipeline The Epidemiology Dynamics Of Hiv In The Six Major Markets Are Discussed Along With Unmet Needs That Have Evolved From The Prolonged Use Of Haart Sales Forecasts Over The Next 10 Years For The Each Of The Late-Stage Drugs
- Highlights
- Class Drug Resistance Represents A Major Problem For The Nnrtis. The Two Late Stage Compounds, Developed By Tibotec/J&J, Address This Issue. Etravirine Is The More Advanced Of The Two, But Rilpivirine Convenient Dosing Schedule Makes It The Commercially More Promising Candidate. New Nrtis In Development Have Not Generated Much Excitement In The Hiv Community Since Most Of These Compounds, Including Avexa's Apricitabine, Achillion's Elvucitabine And Pharmasset's Racivir. Have Only Made Slow Progress Over The Last Few Years. Historically, Emerging Drug Resistance May Have Signaled Overall Treatment Failure And Hastened The Onset Of Aids. While Newer Classes Of Drugs Will Enable Patients With Complex Drug Resistance To Continue With Successful Antiretroviral Therapy, Exactly How They Will Be Incorporated Into Traditional Haart Regimens Remains Unclear At This Stage.
- Reasons To Purchase
- Understand The Constantly Evolving Market Dynamics Of Antiretroviral Drugs Understand The Changing Unmet Needs Of Patients And The Extent To Which Pipeline Drugs Are Addressing These Issues Evaluate The Forecast Of Key Pipeline Antiretroviral Drugs To 2016, Taking Into Account Key Launch Dates, Adressing Of Unmet Needs And Other Factors.
|
|
|
